Investors Buy High Volume of Medline Put Options (NASDAQ:MDLN)

Medline (NASDAQ:MDLN) was the recipient of unusually large options trading activity on Monday. Traders bought 20,689 put options on the company. This is an increase of approximately 326% compared to the typical volume of 4,861 put options.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Two Mills family directors executed very large purchases (~2.58M shares each at ~$29) on Dec. 18, signaling strong insider confidence in the company’s public debut. Read More. Read More.
• Positive Sentiment: Medline completed its IPO and implemented governance changes (Dec. 16), reducing public‑company transition risk and improving investor relations/governance visibility. Read More.
• Positive Sentiment: High‑profile positive media: Jim Cramer said he was “very impressed” with Medline’s IPO, which can attract retail and momentum flows. Read More.
• Neutral Sentiment: The IPO raised roughly $6.26B and delivered a large payday for the Mills family — important for capitalization and ownership structure but mixed for immediate float and liquidity dynamics. Read More.
• Negative Sentiment: Major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares at an average ~$28.37 (Dec. 18), materially reducing their stake and increasing float — a potentially negative supply signal. Read More.
• Negative Sentiment: Unusual options activity: ~20,689 put contracts traded (a ~326% jump vs. average), suggesting short‑term hedging or bearish positioning that could amplify volatility. (Reported Dec. 22)

Insiders Place Their Bets

In other Medline news, Director Andrew J. Mills bought 2,586,206 shares of Medline stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the acquisition, the director directly owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their position. The SEC filing for this sale provides additional information.

Medline Stock Performance

Shares of Medline stock opened at $43.63 on Wednesday. Medline has a 1 year low of $34.89 and a 1 year high of $44.30.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.